2025



Annual Trustees Report

The Irish Lung Fibrosis Association

Company Limited by Guarantee

Table of Contents

Welcome and Highlights from 2025: A Message From Our Chairperson

For more than 23 years, ILFA has supported patients, their families, and the wider lung fibrosis community through advocacy, education, research, and direct support. In 2025, we continued to build on this strong foundation, enhancing our ability to meet the needs of our community.

Under the leadership of our CEO, Maureen O'Donnell, ILFA continued to grow and strengthen its capacity to deliver meaningful support to the lung fibrosis community.

2025 was a year of significant growth for ILFA, with revenue increasing by 23%, enabling us to expand our programmes and reach more individuals than ever before.

Throughout the year, our work was guided by four core priorities:

Advocating for equitable patient care
Educating patients, their carers and the wider lung fibrosis community
Supporting research leading to earlier diagnosis and improved healthcare outcomes
Providing high-quality, award-winning supports directly to patients

Our impact is reflected in the strong engagement across our services, including 2,658 exercise class participant sessions, two successful online Patient Information Days, seven "Let's Talk" sessions, and eight educational bursaries awarded to medical professionals.

We increased focus on mental health and wellbeing, delivering a series of Mindfulness courses and a Breath and Resilience Course.

With the valued support of our partner Boehringer Ingelheim, we delivered mental health training for respiratory healthcare professionals, an awareness campaign, "Every Breath Matters – Know the Signs", during Lung Fibrosis Awareness Month that reached an estimated audience of 1.5 million people and a GP information distribution campaign reaching 3,544 GP practices across Ireland.

Our continued growth would not be possible without our dedicated fundraisers, who contributed 64% of ILFA's funding in 2025, as well as our valued corporate partners, including the Central Bank of Ireland, Endeavor Biomedicines, and Boehringer Ingelheim.

Finally, we would like to acknowledge ILFA's Board and Committee members, our Advocates, and all the volunteers who supported us throughout 2025. As we continue to grow and evolve, commitment by volunteers to ILFA's work remains steadfast and central to our success.

Edward Cassidy

Eddie Cassidy
Chairperson

2025 Impact at a Glance

Key achievements from a year of growth

9
Support groups nationwide

1056
YouTube Video Replays

48
Mindfulness Attendees

9
Educational Webinars

2658
Exercise Participant Sessions

1
Research Publication

1M+
People reached with awareness campaign

24
Nurses completed Mental Health Training

3544
GPs Educated

Working Toward Our Vision: to enhance the quality of life for individuals and families living with lung fibrosis.

About ILFA

ILFA was established in 2002 to support people living with lung fibrosis, and to provide education and research into the condition. The charity was founded by a group of volunteers including Nicola Goodbody, the late Terence Moran, Marie Sheridan, and Professor Jim Egan.

ILFA is a small charity, and throughout our history we've benefited from many talented volunteers and staff. While we primarily work in Ireland, we engage in partnerships with other organisations in the EU and abroad to advance the cause of people living with lung fibrosis. Over the past 23 years we have successfully advocated for, educated, and supported the lung fibrosis community. We've engaged in meaningful research that we hope has contributed to the greater body of work that forms lung fibrosis care in Ireland. Over the years our community has grown, and we currently support nearly 1500 members.

We recognise though that there is still a long way to go, and as ILFA continues to grow, building upon the solid foundation from which we were founded, the services we provide and the community we serve will remain at the centre of our focus. The same vision, mission and values that formed our organisation still guide us and remain relevant to our work today.

Our Mission

Help those living with lung fibrosis, and the healthcare staff caring for them by providing evidence-based information, support and practical resources, by advocating for their needs, and by contributing to awareness, education and research in Lung Fibrosis.

Our Values

People are at our heart.
We treat others with **Compassion.**
We are **Advocates** for change.

Our Vision

To enhance the quality of life of individuals and families living with lung fibrosis.

Charity Information

Name
The Irish Lung Fibrosis Association Company Limited by Guarantee (ILFA)

Accountants:
Bradán Accountants
19 College Green
Dublin 2, D02 VH77

Independent Auditors:
Whiteside Cullinan
Fleming Court
Flemings Place
Ballsbridge Dublin D04 N4X9

Bank:
Bank of Ireland, Montrose
Stillorgan Road
Dublin, D04 W201

Solicitors:
Hayes Solicitors, LLP
Lavery House
Earlsfort Terrace
Saint Kevin's
Dublin, D02 T625

Registered Offices
Lavery House
Earlsfort Terrace
Saint Kevin's
Dublin, D02 T625

Correspondence Address:
C/O Carmichael Centre
4 North Brunswick Street
Dublin, D07 RHA8

Company Secretary
Nicola Cassidy

Executive Management
Maureen O'Donnell, CEO

Board Members
- Eddie Cassidy (Board Chair: stepped down 31 December 2025)
- Liam Galvin (Vice-Chair: Appointed Chair 1 Jan 2026)
- Nicola Cassidy
- Professor Jim Egan
- Colin Edwards
- Patricia Jones
- Lynn Fox

Board Committees
Advocacy (M. O'Donnell Chair)
Fundraising (M. O'Donnell Chair)
Governance (N. Cassidy Chair)
Research (C. Edwards Chair)

Registration Numbers
Company Number: 367940
Registered Charity: 20053437
Revenue CHY Number: 15462

Our Board

Eddie Cassidy – Chair

Eddie Cassidy is Chairperson of the Irish Lung Fibrosis Association. He Joined ILFA in 2007 after caring for his wife Denise, who was diagnosed with Idiopathic Pulmonary Fibrosis in 2003. His personal life experience of caring for a loved one with lung fibrosis has influenced his commitment to ILFA, its mission and values. Eddie was elected Chair in 2018 having previously served as Treasurer for 4 years and as a Director since 2016. Eddie is a member of the Advocacy Committee.

Liam Galvin – Vice Chair

In addition to his volunteer position with ILFA, Liam also helped to found and remains involved in the European Pulmonary Fibrosis Federation (EU-PFF). He is the elected chair of the European Lung Foundation Patient Advisory Committee and the Patient co-chair of the EU funded European Reference Network for Rare Respiratory Diseases (ERN-LUNG). Liam was appointed as ILFA's Board Chair in January 2026 and is a member of the Governance committee. His work is inspired by his family having been deeply impacted by lung fibrosis. He recently received a Lifetime Advocacy Award from the EU-PFF.

Nicola Cassidy - Company Secretary

Nicola joined the ILFA Board in 2007, became a Director in 2016, and was appointed as ILFA's Company Secretary in 2023. She chairs ILFA's Governance committee and serves on the Advocacy, Research, and Fundraising committees. She also coordinates the PPI Research Advisory Group. She has a background in clinical science and a special interest in ILD research and health literacy. Nicola cared for her mother Denise when she was diagnosed with IPF and her health deteriorated.

Professor Jim Egan - Founder/Board Member

Professor Jim Egan is a Consultant Respiratory and Lung Transplant Physician at the Mater Misericordiae University Hospital (MMUH). He began working at MMUH in 2000 where he supported the development of the National Lung Transplant Service which began in 2005. He served as Director of Organ Donation Transplant Ireland (ODTI) 2011-2016 and in 2020 was appointed as Executive Clinical Director of the MMUH. In addition to his clinical work, Professor Egan is one of the four founding members of ILFA.

Our Board

Colin Edwards - Board Member

Colin joined ILFA's Board in 2024. He is founder of Merlin Consulting and a co-founder of patientMpower, an Irish digital health company focused on lung and kidney health. Colin retired from patientMpower in 2022 but continues as an advisor and board member. He currently serves on the boards of the Irish Lung Fibrosis Association and Siel Bleu Ireland. Colin is Chair of ILFA's Research committee and supports the Patient and Public Involvement (PPI) Research Advisory Group.

Lynn Fox - Board Member

Lynn began her nursing career over 20 years ago and currently works as a Respiratory Advanced Nurse Practitioner at the Mater Misericordiae University Hospital. She is committed to raising awareness of ILFA and the valuable support it provides to the lung fibrosis community. Lynn is a member of ILFA's fundraising committee.

Patricia Jones - Board Member

With a nursing career spanning over four decades, Patricia is dedicated to compassionate, patient-centred care. After qualifying as a registered nurse in St Vincent's University Hospital, she pursued further education in respiratory nursing and advanced healthcare at University College Dublin, Aintree University Liverpool, and the Royal College of Surgeons Ireland. Patricia specialises in respiratory nursing, supporting patients across hospital and community settings. She is a proud voice for the nursing profession and a strong advocate for community-based respiratory care.

Our Staff

Maureen O'Donnell - Chief Executive Officer

Maureen is ILFA's Chief Executive Officer. Prior to taking up the role, she ran the Responsible Business Audit Programme for Business in the Community Ireland. She has also held a variety of leadership roles in start-ups, social enterprises, and the charity sector in Ireland, and has significant industry experience in Finance and Information Technology in the US. She holds a Master's Degree in Business and Bachelor's Degrees in Finance and English Literature. She serves on the Board of The Wheel and is a member of ILFA's Advocacy, Governance, Research, and Fundraising committees.

Kelly McVicker – Administrative Lead

Kelly joined ILFA as our Administrative Lead in 2025. She has worked in the charity sector for almost 15 years, with previous roles based around governance and membership across organisations including Retina International and Active Retirement Ireland. Kelly considers the opportunity to work closely with ILFA's members as a key benefit of her role. She has studied Company Secretarial Law and HR Management, and recently completed a diploma in Marine Biology. Kelly serves on ILFA's Governance committee.

Gemma O'Dowd – Stakeholder Engagement Lead

Gemma has worked with ILFA since 2016, first as the Administrative Lead and then in 2025 took up the role of Stakeholder Engagement Lead. In her role, Gemma manages valued relationships with patients, family members, healthcare professionals, fundraisers, pharmaceutical and oxygen companies, corporate partners, and other stakeholders. She also engages with ILFA's network of Lung Fibrosis Support Groups in Ireland and facilitates establishing new in-person and on-line groups also. Previously, Gemma worked with leaders of corporate industry for 30 years. She serves on ILFA's Fundraising committee.

Our Board Committees

ILFA's four committees of the Board in 2025 were:

- **Advocacy**
- **Fundraising**
- **Governance**
- **Research and associated Patient and Public Involvement (PPI) Research Advisory Group**

ILFA Advocacy Committee

Committee Members: Maureen O'Donnell (Chair), Nicola Cassidy, Jim Egan, Eddie Cassidy. The committee is advised by Kathleen O'Meara.

Committee Meetings: 11 April, 29 May, 26 June

Aims: The advocacy committee identifies critical issues affecting ILFA members and the lung fibrosis community which form the foundation of its advocacy work. It makes recommendations to the Board regarding public policy. It monitors and recommends improvements to the processes by which ILFA members are included in the role of public policy formation. It supports and engages in public policy debate, advocacy and campaigning.

Key Success: The committee's work in 2025 was largely focused on getting the State funding which had been allocated to lung fibrosis in 2024 by the Department of Health, released for patient services. Members of the committee met with TDs, issued parliamentary questions, and attended meetings with the HSE and Department of Health. The committee launched ILFA's Strategy for Innovation in Lung Fibrosis Care at Leinster House in June with over 40 TDs, Senators, and parliamentary staff in attendance. The committee prepared an annual budget submission in July, seeking funding for key priorities like an ILD registry, pulmonary rehabilitation, and affordability measures to reduce the financial burden on patients. Members of the committee met with the Minister for Health, the Department of Health and the HSE in late August. Following this meeting, the HSE negotiated and signed a service agreement to fund a pulmonary rehabilitation pilot, a nursing advice line, a psychological counselling grant system, and additional exercise classes to be carried out in 2026.

The focus of the committee in 2026 is on ensuring the sustainability of the funding received, on transplants, and on implementing the recommendations made by the Clinical Advisory Lead which will transform lung fibrosis care in Ireland.

ILFA Fundraising Committee

Committee Members: Maureen O'Donnell (Co-Chair), Gemma O'Dowd (Co-Chair), Nora McNamara, Lynn Fox, Nicola Cassidy, Gerry Redican, Oonagh Ffrench, Edel Mannion, Rachael Pender and Joe Browne.

Committee Meetings: 19 August (inaugural meeting) and 29 October

Aims: The Fundraising Committee provides strategic oversight and guidance to support ILFA's long-term financial sustainability. The Committee seeks to strengthen and diversify income streams, develop relationships with donors and corporate partners, support community fundraising initiatives, and identify new funding opportunities. Through its work, the Committee helps ensure that ILFA can continue to expand its services and supports for people living with lung fibrosis and their families.

Key Successes: During 2025, the committee helped shape ILFA's future fundraising strategy by identifying opportunities to strengthen fundraising infrastructure, support volunteer fundraisers and develop sustainable income streams. Members proposed the development of fundraising resources, event templates and a fundraising calendar to encourage greater community participation and support.

The Committee supported ILFA's World Lung Day Cycleathon in Dublin, delivered in partnership with employees of the Central Bank of Ireland. The event successfully raised awareness of lung fibrosis while generating €1,210 through donations and matched funding.

The Committee also contributed ideas and planning for future fundraising activities, including the development of a flagship fundraising event for 2026, with options such as a national Golf Classic and community-based events explored as opportunities to increase income and engagement.

During it’s first year of operation, the Committee established a strong foundation for growing ILFA's fundraising capacity.

ILFA Governance Committee

Committee Members: Nicola Cassidy (Chair), Colin Edwards, Maureen O'Donnell, and Kelly McVicker.

Meetings: 9 October (inaugural meeting) and 10 December

Aims: The Governance committee was established to support the Board in fulfilling its responsibilities in relation to achieving and observing good governance practice, the efficient and effective conduct of Board and committee meetings, ensuring induction and continuing professional development of the Board as well as overseeing compliance with ethical and conduct obligations of Board and committee members.

Key Successes: In 2025 the Governance committee provided support and oversight into the Charity Regulatory Authority (CRA) compliance submission. The committee also reviewed ILFA's risks and ensured mitigation systems were in place as well as regular review of risks by the designated parties responsible. The committee planned and conducted ILFA's AGM in September and ensured that all filings were made in accordance with the Companies Registration Office (CRO), Charity Regulator, and other authorities. The committee vetted and proposed two new Board members to be coopted in 2026, and as part of its succession and development planning for the Board, developed the annual Board strategy day to be conducted in February 2026.

In 2026 the key focus of the Committee will be updating the Board Handbook and associated policies and Codes as well as succession planning to ensure a diverse and thriving Board.

ILFA Research Committee

Committee Members: Colin Edwards (Chair), Nicola Cassidy, Sean O Sé, Robert Hurley, Maureen O'Donnell

Committee Meetings: 11 February, 27 May

Aims: The aim of the Research Committee is to provide oversight of research conducted by or on behalf of ILFA and provide feedback to the ILFA Board and other relevant stakeholders. The committee also provides guidance and support for ILFA's Patient and Public Involvement (PPI) Research Advisory group.

Key Successes: In 2025, the Research Committee played a key role in advancing knowledge and influencing future service development for interstitial lung disease (ILD) largely through its work with a landmark study examining stakeholder attitudes toward a national ILD registry. The research was both published in the Irish Medical Journal and presented at a national HSE conference, helping to inform ongoing discussions around improving patient data and care planning in Ireland.

Members of the committee also reported on antifibrotic prescribing trends which provided valuable real-world insights into treatment patterns. This research was presented at the Irish Thoracic Society Annual Scientific Conference.

Members also continued their engagement at the global level, participating in the European Respiratory Society Research Conference, the US Pulmonary Fibrosis Federation Summit, and other events which supported ILFA's continued alignment with emerging evidence and best practices for people living with lung fibrosis.

In 2026, the committee is focused on developing a research strategy to support future funding that will address key stakeholder priorities. The committee is also seeking to strengthen its governance by recruiting healthcare professionals and by integrating the PPI Group into research planning and implementation.

ILFA's Patient Public Involvement (PPI) Research Advisory Group

Members: Sean O'Se, Nicola Cassidy, Annette Cremin, Matt Cullen, Colin Edwards, Maureen O' Donnell, Gemma O' Dowd, Mari Ozaki, Dermot Rafferty, Robert Hurley, Ann Markey, Noreen O' Carroll, Prof John Baugh, Carita Bramhill, Chiara Di Santi.

Meetings: 18 March, 23 June, 21 October, 3 December

Aims: The Patient Public Involvement (PPI) Research Advisory Group aims to ensure that the voices of people living with lung fibrosis are represented in research. By bringing together patients, carers, researchers and healthcare professionals, it contributes to the design and development of research, informs advocacy and public policy, and supports studies intended to improve healthcare services. The group plays a key role in promoting patient-centred research and ensuring that the lived experience of the lung fibrosis community shapes future care and treatment developments in Ireland.

Key Successes: In 2025, working with the Advocacy committee, the group successfully advocated for the inclusion of ILD information within the HSE A to Z Conditions website listing. The group also contributed to key research initiatives, including a mental health and wellbeing in ILD study and the Genome of Ireland project. Members of the PPI group also supported the Advocacy committee's launch of ILFA's Strategy for Innovating Lung Fibrosis Care in Ireland at Leinster House in June.

The PPI supported the development and dissemination of research evidence, with ILFA's study on stakeholder attitudes toward a national ILD registry and a paper on the methodology of ILFA's online exercise programme both accepted for publication in the Irish Medical Journal. Members also developed a survey examining the benefits and safety of ILFA's online exercise classes to inform future service delivery.

The group's expertise was further strengthened by the appointment of Professor John Cullen of Maynooth University as a member late in 2025. In 2026, the group's focus will continue to be on supporting and informing lung fibrosis research across Ireland.

Leadership and Governance

The Irish Lung Fibrosis Association (ILFA) is a registered charitable company in Ireland, limited by guarantee and not having a share capital, in accordance with Part 18 of the Companies Act 2014.

The charity is registered with the Charities Regulator under Registered Charity Number (RCN): 20053437 and was granted charitable tax exemption under CHY Number: 15462, pursuant to Section 207 of the Taxes Consolidation Act, 1997.

ILFA is in compliance with the Governance Code for Charities and maintains a record of compliance available for the Regulator to review.

ILFA is governed by its Constitution, dated September 2024. In the event of the charity being wound up, each member's liability is limited to €1, in line with the terms of the company's guarantee. As a company limited by guarantee, ILFA has no beneficial owners. Therefore, the senior managing officials, which include the Board of Directors, have been recorded in the Register of Beneficial Owners in compliance with regulatory requirements.

ILFA has a small dynamic team headed by a Chief Executive Officer who reports directly to the Board through the Chairperson. The CEO is not a member of the Board.

ILFA is governed by a voluntary Board of Trustees who provide leadership and oversight to ensure ILFA's mission and values are upheld.

The following decisions are reserved for the Board:

- The Company's strategic plans and annual operating budgets;
- Projects outside the scope of the annual plan;
- Business acquisitions and disposals;
- Decisions on litigation;
- Appointment/removal of committee Chairs and members;
- Appointment/removal of the Chief Executive Officer;
- Appointment/removal of auditors;
- Approval of borrowing/finance facilities;
- Approval of supplier contracts with terms exceeding one year or financial liability on ILFA exceeding €10,000;
- Ongoing review of risk and internal controls;
- Board governance and oversight

Board members are recruited and coopted through nomination by existing members. New members are proposed and voted on at the Annual General Meeting (AGM) and formally registered with the Companies Registration Office. While there are currently no fixed term limits, Board membership is reviewed annually at the AGM and succession planning is a priority agenda item both for the Board and the Governance committee.

All new Board members receive an induction, which includes training on ILFA's governance policies, code of conduct, and ethical responsibilities. Ongoing training is provided as needed to support members in fulfilling their duties effectively.
The Board is responsible for providing strategic leadership, overseeing the CEO, maintaining financial oversight, and ensuring compliance with laws and ethical standards. Members actively participate in Board meetings, committees, and ILFA activities, and commit to collective decision-making in line with ILFA's values.

ILFA's Board operates under a Board Handbook and is guided by a Code of Conduct and a Conflict of Interest and Declaration of Loyalty Policy, last reviewed in September 2022. Board members declare any relevant interests on appointment and update the Register of Interests annually. All governance policies are reviewed on a scheduled basis or as conditions require.

ILFA is committed to involving its community in shaping its direction. In 2025, ILFA held a World Café event—an online facilitated discussion—to gather stakeholder insights as part of a mid-point review of its strategic plan. The session was structured around ILFA's four core aims (Advocacy, Education, Research, and Support) with small group discussions designed to identify strengths and areas for future development. Additional engagement mechanisms, such as direct contact with service users and satisfaction feedback, continue to inform operational decision-making and ensure ILFA remains responsive to the needs of those it serves.

Responsibility for the implementation of ILFA's strategic plan as agreed by the Board is delegated to the Chief Executive Officer. Delegated functions include annual planning, pursuit of new income sources, developing new programmes, directing resources and spending in line with the approved budget, acting as ILFA's principal spokesperson, reporting, and regulatory compliance.

ILFA maintains a performance management system which includes an annual review for all members of staff carried out by the CEO (except in the case of the CEO which is carried out by the Board Chair).

2025 Board Meetings and Attendance

(Note Operations Are Discussed at Each Meeting)

- **January 27th .... 2024 Year End Review**
- **February 15th .... Board Strategy Day**
- **March 24th .... 2025 Plan/Budget Approval**
- **April 24th .... 2025 YTD Financial Review**
- **June 30th .... Audited Accounts Approval**
- **August 18th .... Planning for Lung Health Awareness Month**
- **September 22nd .... AGM**
- **November 3rd .... Financial, and Risk Review**
- **December 15th .... Year End Discussion/2026 Planning**

Board Member	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep (AGM)	Oct	Nov	Dec
Eddie Cassidy	✓	✓	✓	✓		✓		✓	✓		✓	✓
Liam Galvin	✓	✓	✓	X		X		✓	✓		✓	✓
Nicola Cassidy	✓	✓	✓	✓		✓		X	✓		✓	✓
Colin Edwards	✓	✓	✓	✓		✓		✓	✓		✓	✓
Patricia Jones	✓	✓	✓	✓		✓		✓	✓		X	✓
Lynn Fox	X	✓	X	X		X		✓	✓		X	✓
Jim Egan	✓	✓	✓	✓		X		X	✓		✓	X

✓ = Attended X = Did not attend

ILFA Strategy 2022-2027

The landscape of lung fibrosis care in Ireland is one of evolving progress tempered by persistent challenges, with the charity sector and ILFA in particular playing a pivotal, often indispensable, role. Lung fibrosis is a progressive, life limiting disease, and because of its relative rarity, diagnosis remains a critical hurdle.

While awareness is growing, early and accurate diagnosis can still be elusive, often leading to delayed care. With a disease as severe as lung fibrosis, a delayed diagnosis can shorten patients' lives. Access to specialist multidisciplinary teams, essential for comprehensive care, is not uniform across the country, creating disparities in patient journeys.

Treatment options, particularly anti-fibrotic medications, have transformed the prognosis for some patients, slowing disease progression. However, these treatments are not universally effective, and access to these therapies and to clinical trials as well which can lead to new and improved therapies can be limited, often requiring patients to travel to one of eight specialist centres, most of which are in Dublin.

This is where Ireland's dedicated charity sector, exemplified by ILFA becomes vital. ILFA works tirelessly to fill the gaps in care, offering crucial support, education, and advocacy for patients and their greater lung fibrosis community. ILFA's initiatives include providing patient education materials, a non-medical support line, linkage to support groups across the country, and facilitating access to mental and physical health classes that enhance quality of life.

Furthermore, ILFA actively engages in research, which is fundamental to understanding the disease better and to discovering new treatments. ILFA also advocates on behalf of the lung fibrosis community with the Irish Government and the HSE for improved healthcare policies and services, and better access to diagnostics and therapies.

ILFA's most recent strategy (2022-2027) outlines three core objectives for the organisation:

- Develop and deliver new or improved support services and resources to meet the current and future needs of the lung fibrosis community.
- Strengthen ILFA's ability to deliver on our mission and vision.
- Be a voice for the lung fibrosis community by raising awareness of issues and driving positive change.

In 2025, progress was made against each of these objectives which included:

- New health and wellbeing offerings.
- Education and awareness campaigns targeted to patients, their caregivers, healthcare professionals, and the Irish society.
- Successfully advocating for the release of State funding previously sought for lung fibrosis care.

Risks

Per ILFA's risk management policy (updated in 2025 and reviewed every three years or as circumstances require), ILFA maintains a formal risk management system which includes a risk register. The risk register outlines ILFA's principal risks across six categories as determined by the Board, Staff, and other key stakeholders. It measures risk severity, frequency, and includes mitigation activities for all risks.

The Board reviews the risk register annually and each committee of the Board reviews relevant risks as a standing agenda item at committee meetings. It's worth noting that in 2025 all identified risks were either at a green (mitigated) or yellow (in active mitigation) status.

A key risk identified that remained in active mitigation in 2025 included a lack of funding diversity. ILFA has supported lung fibrosis patients for more than 20 years, and across that time horizon, despite our significant contributions, we have never received meaningful State funding. Over 90% of ILFA's funding comes from individual fundraising and corporate partnerships and this lack of diversity in funding is a risk to our sustainability.

In 2025 ILFA developed a funding strategy intended to diversify funding sources, with specific actions to take that will mitigate the risk and result in a more diverse funding mix, specifically increasing State funding and other grants.

A second key risk that remained in active mitigation in 2025 was related to an overreliance on a small number of longstanding volunteers, particularly with respect to Board membership. In 2025 the Board met to discuss its overall governance and began to establish Board committees with additional volunteers from our community that could support Board succession planning and diversify our volunteer base.

All other risks identified in the risk register were mitigated.

How We Measure Impact

Ideal Patient Outcomes and Levers



Exercise Classes - Participant Numbers



Key Metrics 2025 - ILFA's key metrics for 2025 included Exercise Class Participant Sessions, Webinar Views, GP Education Leaflets distributed, Mindfulness Course attendees, Ecumenical Service Attendees and Patient Packs distributed. We also track educational bursaries to medical professionals.

Community Impact
Annette's Story

On the 3rd of July 2010 my sister Joan died from Idiopathic Pulmonary Fibrosis (IPF). She was only diagnosed six months previously. At the end of 2017, I developed a dry cough and ignored it at first as it only lasted a short time. However, suspecting that it could be serious, I requested a consultation with the Respiratory Physician who looked after my sister.

In March 2018 I was diagnosed with IPF and was advised to make contact with The Irish Lung Fibrosis Association for advice and help.
Gemma was my contact person and she supplied me with all the relevant data pertaining to my diagnosis. I was struggling with the diagnosis which impacted at the time on my daily life, and also with the loss of my sister.

Following the advent of Covid, ILFA commenced online Respiratory Exercise and Rehabilitation classes, run by a qualified Physiotherapist on a weekly basis and such was the interest in the classes that they are now having the class 5 days a week. I also received advice on contacting a Physiotherapist and Dietician, and was very thankful to both for their help. Advice on rehabilitation, diet and nutrition proved very beneficial in my daily life.

ILFA also organises Patient Information Days, delivered by Respiratory Physicians, Nurse Practitioners, Respiratory Physios, Dieticians and Patients that are most informative and helpful.

We also attend ILFA's regularly scheduled online "Let's Talk" sessions which provide information on different topics relating to Pulmonary Fibrosis (eg Medication), Palliative care, Vaccines, Managing Anxiety, Slips Trips and Falls, Oxygen Therapy, Social Services Information, Hospital Appointments and much more. Yoga and Sing Strong have been added to the list in 2026 and are very popular too.

Over the years, ILFA has become an invaluable source of support, information and encouragement for me. From the time of my diagnosis, through the challenges of living with IPF and coping with the loss of my sister, the Association has provided practical advice, exercise opportunities and a strong sense of community.

The exercise classes, information days and "Let's Talk" sessions have helped me to better manage my condition, stay informed and feel less isolated, while newer initiatives such as Yoga and Sing Strong continue to improve the support available to patients. I am grateful for the care and guidance I have received through ILFA, which has made a significant difference to my quality of life

Advocacy Impact

1 Ministerial Meeting

11 Parliamentary Questions

Launch Strategy for Equitable Care 11th June

2026 Pre Budget Submission 28th July

1 AV Room Briefing

Strategic Objective:
ILFA advocates across all levels of the political system for our members. Every day the HSE, Government departments, and State agencies make important decisions about the policies and resources that affect the lives and wellbeing of people with lung fibrosis. We aim to influence those decisions for the benefit of the lung fibrosis community.

2025 Impact:
Our advocacy in 2025 was centered on getting the allocated funding we had advocated for in 2024 released for patient services. We engaged in a number of advocacy initiatives, but a key meeting that proved pivotal in moving the priorities forward was with the new Minister for Health in late August.

Following this meeting, the HSE negotiated and signed a service agreement with ILFA to fund a pulmonary rehabilitation pilot, a nursing advice line, a psychological counselling grant system, and additional exercise classes to be carried out in 2026.

It took longer than we'd hoped, but in the end we prevailed thanks to our members who advocated with us throughout 2025. From contacting and meeting with TDs and Senators, to sharing your stories in the Dáil, on radio, in print media, and at our World Lung Day event, your contributions were invaluable. We are deeply grateful for all of these efforts, including those who joined us in meetings with the Minister and other key decision-makers across the political system.

Education Impact

932
Educational Webinar Views

€4000
Educational Bursaries Issued

3544 + 1.5M
GP + General Public Education Campaign Reach

24 HCP
Mental Health Training Attendees

587
Patient Packs Distributed

Strategic Objective:
ILFA are committed to supporting educational opportunities for healthcare professionals to learn about pulmonary fibrosis and to empowering patients and families with the condition through webinars, guidance, and other evidence based information.

2025 Impact:
In June, Boehringer Ingelheim funded a Mental Health Training Day for Healthcare Professionals at the Mater Misericordiae University Hospital. The event provided training on compassionate communication, self-care and colleague wellbeing. Participants also received valuable insight into the patient experience.

The event highlighted the importance of integrating emotional support into lung fibrosis care and was very well received by attendees.

The Hospital Saturday Fund funded a Breath, Creativity and Resilience Programme, a six-week online course designed to support the emotional wellbeing of people living with lung fibrosis. The programme brought together expert speakers from Ireland's health and wellbeing community to explore topics including resilience, self-compassion, breathwork, and creativity. Participant satisfaction rating was 4.65 out of 5, with feedback highlighting the value of the skills learned and the sense of community developed throughout the programme.

Boehringer Ingelheim also funded September’s Lung Fibrosis Awareness Month - Every Breath Matters campaign. Over the course of September 2025, the radio, print, postal mailing and social media campaign reached 1.5 million people and 3544 GPs across Ireland.

Research Impact

Strategic Objective:

To advance patient-centred research that improves the lives of people living with lung fibrosis. ILFA works to support research initiatives, promote patient and public involvement, disseminate research findings and contribute to the evidence base needed to improve diagnosis, treatment, services and quality of life for people affected by lung fibrosis.

2025 Impact:

In 2025, ILFA issued several publications from its research. Research examining stakeholder attitudes towards a national lung disease registry was published in the Irish Medical Journal and presented at national scientific conferences, helping to inform discussions on the future development of disease registries in Ireland. ILFA also completed a survey exploring the benefits and safety of its online exercise programme, generating evidence to support increased access to virtual pulmonary rehabilitation services for people living with interstitial lung disease.

ILFA strengthened its engagement with the wider research community through participation in the Rare Disease Research Conference, where key topics included disease registries, clinical trials and patient and public involvement in research.

Patient and Public Involvement (PPI) Research Advisory Group

ILFA's PPI Group remained continued its work in 2025, ensuring that the lived experiences of people affected by lung fibrosis informed research and service development. At regular PPI meetings and in member participation in research projects, the group shared their experiences, perspectives and insights, helping to shape research that addresses the issues most important to patients and families.

A notable example of PPI impact was involvement in the Mental Health and Wellbeing in ILD Research Project, led by Dr Elizabeth O'Brien and her team at the Mater Hospital. PPI members provided feedback on the design of the study and participated as well, helping to ensure that the research reflected the real-world experiences and needs of people living with lung fibrosis.

This collaborative approach highlights the important role that patients play in advancing research and improving outcomes for the wider lung fibrosis community.

Support Impact

50 Mindfulness Course Attendees

2658 Exercise Class Participant Sessions

922 Let's Talk Participants & Watch Backs

100+ Ecumenical Service Attendees

171 Patient Information Day Attendees

Strategic Objective:
To provide accessible, person-centred support services that enhance the physical, emotional and social wellbeing of people living with lung fibrosis and their families. ILFA aims to reduce isolation, promote self-management, and ensure that individuals affected by lung fibrosis can access meaningful peer support, wellbeing programmes and opportunities to improve their quality of life.

2025 Impact:
ILFA continued to expand its support services in 2025, increasing the number of support groups to nine and extending access to peer support across Ireland. ILFA's online exercise classes remained a cornerstone of our support offering, running three times weekly throughout the year with increasing demand and consistent participation. During the summer and at Christmastime there were yoga classes offered with good participation in each session.

HSE National Lottery provided a grant for us to host six Mindfulness six-week online courses through the year, helping 50 participants develop practical techniques to manage stress, build resilience and support their emotional wellbeing.

In October, ILFA‘s annual remembrance service provided its more than 100 attendees with an opportunity to come together in community to reflect upon the lives impacted by lung fibrosis.

Collectively, our programmes demonstrate ongoing commitment to supporting the holistic needs of people living with the disease.

Treasurer's Statement

The Irish Lung Fibrosis Association is committed to the utmost transparency and accountability to our stakeholders. Our annual audited accounts are published on our website after they are approved by the Board. Our website also contains the audited accounts for previous years alongside our annual reports and updates on our activities. ILFA's management accounts are supported by a certified accountancy and book-keeping practice and are independently audited on an annual basis.

ILFA's 2025 financial year ran from the 1st of January to the 31st of December. Once again, as in previous years we received the majority of income from individual acts of generosity and community fundraising. Our fundraisers used creative methods, which ran alongside popular events like the VHI Women's Mini Marathon. Online funding platforms are now widely used by our fundraising community.

The Board gratefully acknowledges the kindness of legacy bequests and donations from the families of those within our community who lost their brave battle with lung fibrosis. Additionally, support from our our corporate partnerships is vital.

In 2025 general donations comprised 64% of ILFA's revenue, with the balance from Corporate and State funding and applied grants. ILFA grew revenue by 23% in 2025 which enabled us to provide more programmes and services. We expanded our team and brought on a full time Administrative Lead, a significant step for day to day operations, and a Stakeholder Engagement Lead to support future growth. Our CEO managed our small team of staff and contractors to effectively deliver ILFA's patient-centred programmes.

In the year to 31 December 2025, the cost of salaries, projects, and other expenses came to €277,167 whilst general income was €290,591 and income from investments was €1,429 resulting in a small surplus of €14,853 for the financial year. The surplus will be added to the reserves to support ILFA's future investment in growth. We are fortunate that income continued to grow in 2025, allowing us to invest in additional services, supports and education for the lung fibrosis community without dipping into reserves. The reserves in 2025 continued to be slightly in excess of the policy of one year's operational budget. ILFA retains unrestricted cash reserves in order to continue its work even in the face of an increasingly unpredictable economic environment.

As we move into 2026, ILFA has been the beneficiary of a significant restricted grant from the HSE that will allow us to once again expand our service portfolio while maintaining sufficient liquidity to support our strategic mission and objectives.

Colin Edwards

Colin Edwards
Treasurer (2026)

Statement of Directors Responsibilities

The directors are responsible for preparing the Directors* Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:
select suitable accounting policies for the company financial statements and then apply them consistently; make judgements and accounting estimates that are reasonable and prudent; state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014 and enable the financial statements to be readily and property audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of Information to Auditor
Each persons who are directors at the date of approval of this report confirms that: there is no relevant audit information (information needed by the company's auditor in connection with preparing the auditor's report) of which the company's auditor is unaware, and the directors have taken all the steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

Signed on behalf of the board

Colin Edwards

Colin Edwards
Director

Liam Galvin

Liam Galvin
Director

The original financial statements were approved and signed by the directors on:

Date: 8th June 2026

Independent Auditor’s Report

Opinion

We have audited the financial statements of The Irish Lung Fibrosis Association CLG ('the company') for the financial year ended 31 December 2025 which comprise the Income Statement, the Balance Sheet, the Cash Flow Statement and the related notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” issued in the United Kingdom by the Financial Reporting Council.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2025 and of its surplus for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 4 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other Information
The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014
In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception
Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective Responsibilities

Responsibilities of directors for the financial statements
As explained more fully in the Directors' Responsibilities Statement set out on page 5, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is contained in the appendix to this report, located at page 8, which is to be read as an integral part of our report.

The purpose of our audit work and to whom we owe our responsibilities
Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Mark Hamill

Mark Hamill
for and on behalf of
WHITESIDE CULLINAN
Registered Auditor and Chartered Accountants

Financial Activities

Income Statement

for the financial year ended 31 Dec 2025

	2025 €	2024 €
Income	**290,591**	**225,252**
Expenditure	**(277,167)**	**(251,504)**
Surplus/(Deficit) before interest	**13,424**	**(26,252)**
Investment income	**68**	
Other gains and losses	**1,361**	
Total comprehensive income	**14,853**	**(26,252)**
Retained surplus brought forward	**339,526**	**365,778**
Retained surplus carried forward	**354,379**	**339,526**

The original financial statements were approved by the Board on 8 June 2026 and signed on its behalf by:

Colin Edwards
Director
Colin Edwards

Liam Galvin
Director
Liam Galvin

Balance Sheet

for the financial year ended 31 Dec 2025

	Notes	2025 €	2024 €
Fixed Assets			
Investments	8	2,797	1,436
Current Assets	9		
Debtors		2,148	5,535
Cash and cash equivalents		406,207	362,464
		408,355	367,999
Creditors: falling due within one year	11	(56,773)	(29,909)
Net Current Assets		351,582	338,090
Total Assets less Current Liabilities		354,379	339,526
Reserves			
Retained surplus		354,379	339,526
Equity attributable to owners		354,379	339,526

The financial statements have been prepared in accordance with the small companies' regime.

The original financial statements were approved by the Board on 8 June 2026 and signed on its behalf by:

Colin Edwards Colin Edwards
Director

Liam Galvin Liam Galvin
Director

Cash Flow Statement

for the financial year ended 31 Dec 2025

	Notes	2025 €	2024 €
Cash flows for operating activities			
Surplus/Deficit for the financial year		14,853	(26,252)
Adjustments for:			
Investment income		(68)	-
Fair value gains and losses		(1,361)	-
		13,424	(26,252)
Movements in working capital:			
Movement in debtors		3,387	(2,335)
Movement in creditors		26,864	25,713
Cash generated from/(used in) operations		43,675	(2,874)
Cash flows from investing activities			
Dividends received		68	-
Payments to acquire investments		-	(1,436)
Net cash generated from/(used in) investment activities		68	(1,436)
Net increase/(decrease): cash & equivalents		43,743	(4,310)
Cash and cash equivalents 1/1/2025		362,464	366,774
Cash and cash equivalents 31/12/2025	10	406,207	362,464

Notes to the Financial Statements

1. General Information
The Irish Lung Fibrosis Association CLG is a company limited by guarantee incorporated and registered in Ireland. The registered number of the company is 367940. The registered office of the company is Lavery House, Earlsfort Terrace, Dublin 2. The nature of the company's operations and its principal activities are set out in the Directors' Report

Currency
The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance
The financial statements of the company for the year ended 31 December 2025 have been prepared on the going concern basis and in accordance with generally accepted accounting principles in Ireland and Irish statute comprising the Companies Act 2014 and in accordance with the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland (FRS 102) issued by the Financial Reporting Council.

Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Income
Income comprises the amounts received from donations, fundraising activities and deposit interest receivable.

Grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and grants will be received.

Grants are recognised using the accrual model. Under the accrual model, grants relating to revenue are recognised on a systemic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable. Where grants received are prior to satisfying the revenue recognition criteria, they are recognised as a liability in deferred income.

Grants relating to assets are recognised in income on a systemic basis over the useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

Where a grant becomes repayable, a liability is recognised when the repayment obligation arises.

Investments
Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Income Statement in the year in which it is receivable.

Taxation
The company is a registered charity, CHY 20053437, and has been granted charitable tax exemption under Section 207, Taxes Consolidation Act, 1997. The CHY (Revenue) number is 15462.

3. Departure from Companies Act 2014 Presentation
The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

4. Provisions Available for Audits of Small Entities
In common with many other businesses of our size and nature, we use our auditors to assist with the preparation of the financial statements.

	2025	2024
5. Income from investments	**€**	**€**
Investment income	**68**	**-**

6. Other Gains and Losses

Fair value gains and losses are as follows:		
Investments in shares	**1,361**	**-**

	2025	2024
7. Employees		
The average monthly number of employees	**3**	**1**

8. Investments	**Listed Investments €**
Cost or Valuation	
At 1 January 2025	1,436
Revaluations	1,361
At 31 December 2025	**2,797**
Net book value	
At 31 December 2025	**2,797**
At 31 December 2024	**1,436**

The company received shares by way of a donation during the year ended 31st December 2024 to the value of €1,436. 31st December 2025 the value of those listed shares was €2,797

	2025	2024
9. Debtors	**€**	**€**
Other debtors	-	3,427
Prepayments	2,148	2,108
	2,148	**5,535**

10. Cash and cash equivalents		
Cash and bank balances	100,528	58,061
Cash equivalents	305,679	304,403
	406,207	**362,464**

	2025	2024
11. Creditors	**€**	**€**
Amounts falling due within one year		
Trade creditors	141	16,873
Taxation	3,439	1,919
Other creditors (credit card balance)	801	934
Pension accrual	1,671	1,447
Accruals	8,121	8,736
Deferred Income	42,600	-
	56,773	**29,909**

Deferred income consists of grants received that have not yet satisfied the conditions and revenue recognition criteria attaching to them.

12. Status

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members or within one year thereafter for the payment of the debts and liabilities of the company contracted before they ceased to be members and the costs, charges and expenses of winding up and for the adjustment of the rights of the contributors among themselves such amount as may be required, not exceeding € 2.

13. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

14. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 8th June 2026.

Corporate Partnerships

Thank You

Thanks to our corporate partners for supporting us throughout 2025

We are sincerely grateful to **Boehringer Ingelheim** for their valued support, helping us deliver important education and awareness initiatives.

Support Highlights:

Patient Education

Supported the "Every Breath Matters, Know the Signs" national awareness campaign, helping to raise awareness of lung fibrosis and the importance of early diagnosis across Ireland.

Exercise and Wellbeing

Supported the HCP Mental Health Training Day, providing mental health and wellbeing support to healthcare professionals supporting lung fibrosis patients.

Professional Engagement

Supported a national GP education campaign that provided lung fibrosis information and resources to 3,544 GPs across Ireland.

Banc Ceannais na hÉireann
Central Bank of Ireland
Eurosystem

We extend our heartfelt thanks to the **Central Bank** Charity Committee, Conor McCabe, and all Central Bank staff and volunteers for your transformational support in 2025.

Support Highlights:

- Supported the provision of information packs and exercise classes.
- Allowed ILFA to offer guidance and practical help to patients and their carers during times of uncertainty.
- Supported continued engagement with research and professional development.

Thanks to **Endeavor Biomedicines** who supported us with clinical trial education funding in 2025.

Support Highlights:

Clinical Trials Education - Support with disseminating knowledge to patients and health care professionals around clinical trials including how to participate and what to expect.

<u>To All of Our Corporate Partners:</u> Your support has enabled ILFA to provide patients with real knowledge and empower them to make informed decisions related to clinical trials and future treatment.

Gratitude to Our Community

We would like to express our sincere thanks to all our donors, fundraisers, and volunteers who supported ILFA in 2025. Your generosity, time, and commitment have made a meaningful difference in the lives of those affected by lung fibrosis. Together, we are bringing hope, support, and strength to our community and we couldn't do it without you.

2025 Top Fundraisers

€10,000 +

VHI Womens Mini Marathon
ILFA supporters and friends

Connemarathon
Darren Little

€5,000 +

Paris to Versailles - Brothers Rory, Jamie and Ben

West Kerry Tractor Run - JP O'Sullivan

Ironman Copenhagen - Roberta McDonald

Dublin to Galway Swim - Ed Swain

Dublin City Marathon - Friends, supporters of ILFA

Ceili and Old Time Music Fundraiser - John Joyce and Sally Burke

Bingo Loco Fundraiser - Claire Swan and Mary Leech

Night of Music and Song - Heavey Family and Community Choirs

Chicago Marathon - David Crosby

€2,500 +

45 Card Drive - Bebhinn, Michael and Marguerite

Table Quiz Gortroe - James McAuliffe

Bel Canto Choir Fundraiser - Audrey Robinson

Liverpool Shirt Raffle - Pamela Martin

Cook Medical Mini Marathon - Megan O'Donnell

Clontarf Half Marathon -Rebecca Tansey and Ciaran O'Brien

Vintage Tractor Run -Darren McLaughlin

Carols by Candlelight - UCC Choral Society and Molly Hickey

Company Number: 367940
Registered Charity Number: 20053437
Revenue CHY Number: 15462